Skip to main content Skip to main navigation menu Skip to site footer

The effectivity of single and combined dose of oseltamivir therapy on length of stay of COVID-19 patients in Mataram General Hospital, Indonesia

Abstract

Background: Oseltamivir is an antivirus for the corona virus which is currently used as part of the therapy regiment for COVID-19 patients. This is because the definite antivirus of choice for COVID-19 is yet to be found. The combined administration of oseltamivir and antibiotics compared with oseltamivir alone is known to shorten the hospitalization length of patients with severe respiratory infections in the ICU. However, there is no solid data explaining the effectiveness of oseltamivir, both alone or as part of a combination therapy, in the prevention and treatment of COVID-19 patients. The success of treating confirmed COVID-19 patients who are hospitalized can be seen from the length of patient hospitalization. This study aimed compare the length of hospitalization between patients with confirmed COVID-19 cases receiving oseltamivir alone or in combination with antibiotics.

Methods: This study was conducted using an analytical observational design with a cross sectional approach. The samples were 238 people hospitalized at the Mataram General Hospital who were sampled using a total sampling technique according to the inclusion and exclusion criteria.

Results: Amongst the 238 confirmed COVID-19 patients hospitalized at the Mataram General Hospital, 52.5 % received oseltamivir alone, while 47.5% received a combination of oseltamivir and azithromycin. Analysis showed that there was a significant difference in the length of hospitalization between both groups (p<0.001).

Conclusion: The hospitalization period of patients given oseltamivir-azithromycin combination therapy was relatively shorter than that of patients given oseltamivir alone.

References

  1. WHO. Coronavirus Disease (COVID-19) Situation Report - 128. 2020.
  2. Satgas COVID. Data Sebaran COVID-19 [Internet]. 2020 [Accesed: October, 21st 2021]. Available from: https://covid19.go.id
  3. Diskominfotik. Data COVID-19 NTB [Internet]. 2020[Accesed: October, 21st 2021]. Available from: https://corona.ntbprov.go.id
  4. Shi Y, Wang G, Cai X, Deng J, Zheng L, Zhu H, et al. An overview of COVID-19. J Zhejiang Univ B (Biomedicine Biotechnol. 2020;21(5):343–60.
  5. Okba NMA, Müller MA, Li W, Wang C, GeurtsvanKessel CH, Corman VM, et al. SARS-CoV-2 specific antibody responses in COVID-19 patients. Emerg Infect Dis. 2020;(March):1–18.
  6. Mason RJ. Pathogenesis of COVID-19 from a cell biology perspective. Eur Respir J. 2020;55(4):9–11.
  7. Wu R, Wang L, Kuo HCD, Shannar A, Peter R, Chou PJ, et al. An Update on Current Therapeutic Drugs Treating COVID-19. Curr Pharmacol Reports. 2020;6(3):56–70.
  8. Chiba S. Effect of Early Oseltamivir on COVID-19-Suspected Outpatients without Hypoxia. 2020;1–20.
  9. Ramatillah DL, Isnaini S. Treatment profiles and clinical outcomes of COVID-19 patients at private hospital in Jakarta. PLoS One. 2021;16(4 April):1–11.
  10. Pangarsa EA, Setiawan B, Santosa, Naibaho RM, Rizky D, Suyono, et al. Covid-19 vaccination in patients with cancer: Position paper from the indonesian society of hematology and medical oncology (ishmo) of semarang. Bali Med J. 2021;10(1):142–50.
  11. Albani F, Fusina F, Giovannini A, Ferretti P, Granato A, Prezioso C, et al. Impact of azithromycin and/or hydroxychloroquine on hospital mortality in covid-19. J Clin Med. 2020;9(9):1–10.
  12. Auld SC, Harrington KR V., Adelman MW, Robichaux CJ, Overton EC, Caridi-Scheible M, et al. Trends in ICU Mortality From Coronavirus Disease 2019. Crit Care Med. 2021;1–11.
  13. Vahedian-Azimi A, Mohammadi SM, Beni FH, Banach M, Guest PC, Jamialahmadi T, et al. Improved COVID-19 ICU admission and mortality outcomes following treatment with statins: A systematic review and meta-analysis. Arch Med Sci. 2021;17(3):579–95.
  14. Pascarella G, Strumia A, Piliego C, Bruno F, Del Buono R, Costa F, et al. COVID-19 diagnosis and management: a comprehensive review. J Intern Med. 2020;288(2):192–206.
  15. Echeverría-Esnal D, Martin-Ontiyuelo C, Navarrete-Rouco ME, De-Antonio Cuscó M, Ferrández O, Horcajada JP, et al. Azithromycin in the treatment of COVID-19: a review. Expert Rev Anti Infect Ther. 2021;19(2):147–63.
  16. Beauduy C, Winston L. Tetracyclines, Macrolides, Clindamycin, Chloramphenicol, Streptogramins, & Oxazolidinones. In: Katzung B, editor. Basic & Clinical Pharmacology, 4th edition. New York: McGraw-Hill Education; 2018. p. 815–25.
  17. Sharma Y, Horwood C, Hakendorf P, Thompson C. Effectiveness of Oseltamivir in reducing 30-day readmissions and mortality among patients with severe seasonal influenza in Australian hospitalized patients. Int J Infect Dis. 2021;104:232–8.
  18. Arabi YM, Fowler R, Hayden FG. Critical care management of adults with community-acquired severe respiratory viral infection. Intensive Care Med. 2020;46(2):315–28.
  19. Setiadi AP, Wibowo YI, Halim S V., Brata C, Presley B, Setiawan E. Tata Laksana Terapi Pasien dengan COVID-19: Sebuah Kajian Naratif. Indones J Clin Pharm. 2020;9(1):70–94.
  20. Tan Q, Duan L, Ma Y, Wu F, Huang Q, Mao K, et al. Is oseltamivir suitable for fighting against COVID-19: In silico assessment, in vitro and retrospective study. Bioorg Chem. 2020;(104):1–11.
  21. Wang Z, Ji JS, Liu Y, Liu R, Zha Y, Chang X, et al. Survival analysis of hospital length of stay of novel coronavirus (COVID-19) pneumonia patients in Sichuan, China. medRxiv. 2020;1–16.

How to Cite

Irawan, R., Wanadiatri, H., Musyarrafah, M., Azmi, F., & Rahadianti, D. (2021). The effectivity of single and combined dose of oseltamivir therapy on length of stay of COVID-19 patients in Mataram General Hospital, Indonesia. Bali Medical Journal, 10(3), 1101–1104. https://doi.org/10.15562/bmj.v10i3.2963

HTML
12

Total
30

Share

Search Panel